Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)’s share price shot up 2.3% during trading on Friday . The stock traded as high as $5.01 and last traded at $4.94, with a volume of 819,557 shares changing hands. The stock had previously closed at $4.83.

Several equities research analysts have commented on the company. Brean Capital restated a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Wednesday, June 15th. Jefferies Group restated a “buy” rating and set a $9.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, April 6th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Progenics Pharmaceuticals in a research note on Monday, April 4th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Progenics Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $10.35.

The stock’s 50 day moving average price is $4.77 and its 200-day moving average price is $4.72. The company’s market capitalization is $353.93 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.05. During the same period in the previous year, the company posted ($0.15) earnings per share. The firm earned $2.50 million during the quarter, compared to analyst estimates of $3.27 million. The firm’s quarterly revenue was up 908.1% on a year-over-year basis. Equities research analysts expect that Progenics Pharmaceuticals Inc. will post $0.12 EPS for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.